Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) ...

Roche received a major boost Tuesday when the company announced its experimental oral medication giredestrant successfully reduced the risk of breast cancer returning after surgery, delivering a much ...